Skip to main content
logo
Hansa Biopharma AB (publ) (STO:HNSA)
Sweden flag Sweden · Delayed Price · Currency is SEK
39.42
+8.72 (28.40%)
Jul 24, 2026, 5:29 PM CET

Hansa Biopharma AB Financials Overview

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Revenue
189.46222.27171.32
Revenue Growth
10.59%29.74%-
Gross Profit
108.32138.7187.76
Operating Income
-589.36-520.71-637.88
Net Income
-755.14-534.11-807.24
Earnings Per Share
-7.86-6.58-12.85
EPS Growth
---

Revenue by Geography
Chart
Fiscal YearFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Dec '22 Dec '21
Sweden
-3.12-4.68-
North America
14.0927.9627.4264.2715.71
Europe (Ex Sweden)
202.28140.24106.6885.5718.17
Rest of The World
5.9----
Total
222.27171.32134.09154.5233.88

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Cash & Investments
552.81701.08405.28
Total Debt
1,034938.671,079
Net Cash (Debt)
-480.99-237.59-673.73
Net Cash Growth
---
Net Cash Per Share
-4.93-2.93-10.72

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Cash Flow
-579.63-549.17-674.88
Capital Expenditures
---0.12
Free Cash Flow
-579.63-549.17-675
Free Cash Flow Growth
---

Margins
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Gross Margin
57.17%62.41%51.23%
Operating Margin
-311.07%-234.27%-372.34%
Pretax Margin
-397.41%-239.28%-469.43%
Profit Margin
-398.58%-240.30%-471.20%
FCF Margin
-305.94%-247.08%-394.01%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingJul '26 Dec '25 Dec '24 Dec '23
PS Ratio
16.4915.7315.52-